Plecanatide vs Larazotide
Head-to-head comparison of Plecanatide (Plecanatide) and Larazotide (Larazotide acetate (AT-1001)) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Plecanatide | Larazotide |
|---|---|---|
| Category | Gastrointestinal | Gastrointestinal |
| Full Name | Plecanatide | Larazotide acetate (AT-1001) |
| Molecular Weight | Approx. 1620 Da | N/A |
| Half-Life | Local intestinal action; systemic half-life not clinically meaningful | short; designed for local gut action |
| Amino Acids | 16 | 8 |
| Typical Dose | 3 mg once daily | 0.5-4 mg TID (clinical studies) |
| Route | Oral | Oral |
| Purity | ≥98% | ≥98% |
| Studies Count | 350 | 40 |
| Research Status | Clinical | Clinical |
Plecanatide Benefits
- ✓improves-stool-frequency
- ✓supports-fluid-secretion
- ✓may-reduce-constipation
- ✓local-gut-action
Larazotide Benefits
- ✓tight-junction-support
- ✓reduced-permeability
- ✓symptom-reduction
- ✓barrier-protection
Plecanatide Dosing
3 mg PO daily|take with or without food|avoid when dehydrated
Larazotide Dosing
0.5-4 mg orally before meals in clinical trials|typically three times daily|short-course or chronic study protocols
Plecanatide Side Effects
- ⚠diarrhea
- ⚠abdominal-discomfort
- ⚠nausea
Larazotide Side Effects
- ⚠headache
- ⚠nausea
- ⚠abdominal discomfort
Research Overview
Plecanatide
Clinical trials show plecanatide improves constipation outcomes with a generally favorable tolerability profile. Like linaclotide, it acts locally in the intestinal lumen via GC-C signaling rather than systemic hormone effects.
Larazotide
Clinical and translational studies suggest larazotide can reduce antigen passage across the epithelium and improve gut barrier function. It is one of the better-known peptides for intestinal permeability and barrier-focused gastrointestinal therapy.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.